{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:54:17Z","timestamp":1781585657292,"version":"3.54.5"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      TRK inhibitors targeting\n                      <jats:italic>NTRK<\/jats:italic>\n                      fusion\u2010positive cancers have the potential to improve patient outcomes, but also have high costs. We report the first long\u2010term projections of cancer prevalence associated with\n                      <jats:italic>NTRK<\/jats:italic>\n                      gene fusions in Australia, to 2044.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed national Australian Institute of Health and Welfare incidence (1982\u20132019) and survival (1991\u20132019), NSW Enduring Cancer Data Linkage incidence (1982\u20132019) and survival data (1982\u20132019). We projected 1\u2010year to 5\u2010year cancer prevalence using validated statistical methods, for all stages combined, advanced disease at diagnosis (here, distant metastasis\/lymph node involvement), and advanced disease after progression post\u2010diagnosis. We estimated prevalence for all paediatric cancers combined (age\u2009&lt;\u200918\u2009years at diagnosis), all adult solid cancers combined, 18 cancer types\/groups, and 5 cancer sub\u2010types relevant to current Australian government subsidies of TRK inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For all solid cancers combined, we project increasing prevalence of individuals who were diagnosed with tumours exhibiting\n                      <jats:italic>NTRK<\/jats:italic>\n                      gene fusions, primarily due to population growth and ageing. For example, for 2\u2010year prevalence (aligning with 2.5\u2009years average treatment assumed in previous economic assessments for a TRK inhibitor subsidy), the projected increases from 2019 to 2044 are: all stages combined, paediatric cancers 80 to 106 (+ 32.5%), adult cancers 645 to 970 (+ 50.4%); advanced disease at diagnosis, paediatric cancers 19 to 23 (+ 21.1%), adult cancers 185 to 261 (+ 41.1%); advanced disease after progression post\u2010diagnosis, paediatric cancers 22 to 30 (+ 36.4%), adult cancers 110 to 180 (+ 63.6%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results from this study can support healthcare planning and budget forecasts, including for different potential government treatment subsidy scenarios.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71805","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:56:26Z","timestamp":1779278186000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paediatric and Adult Solid Tumours Exhibiting\n                    <scp>\n                      <i>NTRK<\/i>\n                    <\/scp>\n                    Gene Fusions in Australia, 2020\u20132044: A Population\u2010Based Statistical Modelling Study"],"prefix":"10.1002","volume":"15","author":[{"given":"Qingwei","family":"Luo","sequence":"first","affiliation":[{"name":"The Daffodil Centre The University of Sydney, and Cancer Council NSW  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon\u2010Jung","family":"Kang","sequence":"additional","affiliation":[{"name":"The Daffodil Centre The University of Sydney, and Cancer Council NSW  Sydney New South Wales Australia"},{"name":"Cancer Elimination Collaboration, School of Public Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Cuff","sequence":"additional","affiliation":[{"name":"Research Advocate, the Daffodil Centre  Sydney New South Wales Australia"},{"name":"Faculty of Science Biotech and Biomolecular Science University of New South Wales  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Zalcberg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Alfred Health and School of Public Health and Preventive Medicine, Faculty of Medicine Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Canfell","sequence":"additional","affiliation":[{"name":"Cancer Elimination Collaboration, School of Public Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Steinberg","sequence":"additional","affiliation":[{"name":"The Daffodil Centre The University of Sydney, and Cancer Council NSW  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100987"},{"key":"e_1_2_14_3_1","unstructured":"Australian Government \u201cDepartment of Health and Aged Care. Therapeutic Goos Administration. Guidance and resources: Australian prescription medicine decision summaries \u2010 Vitrakvi 2020 \u201dhttps:\/\/www.tga.gov.au\/resources\/auspmd\/vitrakvi."},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100087"},{"key":"e_1_2_14_5_1","unstructured":"National Institute for Health and Care Excellence \u201cLarotrectinib for treating NTRK fusion\u2010positive solid tumours: Technology appraisal guidance (TA630) \u201dhttps:\/\/www.nice.org.uk\/guidance\/ta630\/chapter\/1\u2010Recommendations."},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.299"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01177-y"},{"key":"e_1_2_14_8_1","unstructured":"U.S. Food and Drug Administration \u201cFDA approves larotrectinib for solid tumors with NTRK gene fusions 2018 \u201dhttps:\/\/www.fda.gov\/drugs\/fda\u2010approves\u2010larotrectinib\u2010solid\u2010tumors\u2010ntrk\u2010gene\u2010fusions."},{"key":"e_1_2_14_9_1","unstructured":"Bayer US \u201cU.S. FDA Grants Full Approval of VITRAKVI (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion\u2010Positive Solid Tumors \u201dhttps:\/\/www.bayer.com\/en\/us\/news\u2010stories\/approval\u2010of\u2010vitrakvi."},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00500"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab274"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.740676"},{"key":"e_1_2_14_14_1","unstructured":"Australian Government. Department of Health and Aged Care \u201cMedicare Benefits Schedule: Genetic testing for NTRK fusion in patients with locally advanced or metastatic solid tumours \u2013 Factsheet \u201dhttp:\/\/www.mbsonline.gov.au\/internet\/mbsonline\/publishing.nsf\/Content\/54B00EA81FF87204CA25886E0018523D\/$File\/Factsheet\u2010Genetic\u2010testing\u2010NTRK%20fusion.24.06.22.pdf."},{"key":"e_1_2_14_15_1","unstructured":"Australian Government. Department of Health and Aged Care \u201cThe Pharmaceutical Benefits Scheme. Larotrectinib: Capsule 25 mg Capsule 100 mg Oral solution 20 mg per mL 100 mL; Vitrakvi \u2010 Public Summary Document (PSD) March 2022 PBAC Meeting \u201dhttps:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac\u2010meetings\/psd\/2022\u201003\/larotrectinib\u2010capsule\u201025\u2010mg\u2010capsule\u2010100\u2010mg\u2010oral\u2010solution."},{"key":"e_1_2_14_16_1","unstructured":"Australian Government. Department of Health and Aged Care \u201cThe Pharmaceutical Benefits Scheme. Larotrectinib: Capsule 25 mg Capsule 100 mg Oral solution 20 mg per mL 100 mL; Vitrakvi \u2010 Public Summary Document (PSD) March 2024 PBAC Meeting \u201dhttps:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac\u2010meetings\/psd\/2024\u201003\/larotrectinib\u2010Vitrakvi\u2010PSD\u2010March\u20102024."},{"key":"e_1_2_14_17_1","unstructured":"Australian Government. Department of Health and Aged Care \u201cThe Pharmaceutical Benefits Scheme. Larotrectinib: Capsule 25 mg Capsule 100 mg Oral solution 20 mg per mL 100 mL; Vitrakvi \u2010 Public Summary Document (PSD) November 2020 PBAC Meeting with December 2020 Addendum updated 01\/04\/2025 \u201dhttps:\/\/www.pbs.gov.au\/medicinestatus\/document\/510.html."},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2025.101537"},{"key":"e_1_2_14_19_1","volume-title":"Cancer data in Australia","author":"Australian Institute of Health and Welfare","year":"2025"},{"key":"e_1_2_14_20_1","unstructured":"Australian Bureau of Statistics \u201cHistorical Population 2016 \u201dhttps:\/\/www.abs.gov.au\/statistics\/people\/population\/historical\u2010population\/2016."},{"key":"e_1_2_14_21_1","volume-title":"Population Projections, Australia, 2017 (Base) \u2010 2066","author":"Australian Bureau of Statistics","year":"2018"},{"key":"e_1_2_14_22_1","unstructured":"Cancer Institute NSW \u201cCanDLe program 2026 \u201dhttps:\/\/www.cancer.nsw.gov.au\/research\u2010and\u2010data\/cancer\u2010data\u2010and\u2010statistics\/candle\u2010program."},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31055-3"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920975613"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.52366"},{"key":"e_1_2_14_26_1","unstructured":"Australian Government Department of Health and Aged Care \u201cThe Pharmaceutical Benefits Scheme: Larotrectinib \u201dhttps:\/\/www.pbs.gov.au\/pbs\/search?analyse=false&term=larotrectinib&base=atc1code:l&search\u2010type=medicines."},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz384"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0090"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00206-y"},{"key":"e_1_2_14_30_1","unstructured":"Australian Government Department of Health and Aged Care \u201cThe Pharmaceutical Benefits Scheme: Background [21\/08\/2023] \u201dhttps:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/deeds\u2010agreement\/background."},{"key":"e_1_2_14_31_1","unstructured":"\u201cGeneric Vitrakvi Availability \u201dhttps:\/\/www.drugs.com\/availability\/generic\u2010vitrakvi.html."},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(22)00090-1"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180033"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-842X.2003.tb00615.x"},{"key":"e_1_2_14_35_1","unstructured":"E.Tracey T.Kerr A.Dobrovic D.Currow andCancer Institute NSW \u201cCancer In NSW Incidence and Mortality Report 2008 \u201d(2010)."}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71805","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71805","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:19:28Z","timestamp":1781583568000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/cam4.71805"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71805","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71805"}}